The aging eye offers unique opportunities to study and understand the aging brain, in particular related to Alzheimer’s disease (AD) and dementia. However, little is known about relationships between eye diseases and dementia-related neurodegeneration.
Objective:
To determine the potential association between three age-related eye diseases and AD and dementia-related neuropathology.
Methods:
We reviewed autopsy data from the prospective longitudinal Adult Changes in Thought (ACT) cohort. ICD-9 codes were used to identify diagnoses of diabetic retinopathy, glaucoma, and age-related macular degeneration. Multivariate regression models were used to determine odds ratios (OR) of neuropathology features associated with dementia, including Braak stage, Consortium to Establish a Registry for AD (CERAD score), Lewy bodies, hippocampal sclerosis, and microvascular brain injury, in addition to quantitative paired helical filament (PHF)-tau levels for people with and without each eye condition. We also evaluated interactions between eye conditions and dementia related neuropathologic findings were evaluated.
Results:
676 autopsies were included. Diabetic retinopathy was significantly associated with increased risk of deep cerebral microinfarcts (OR = 1.91 [95% confidence interval (CI) 1.11, 3.27], p = 0.02). No other significant association or interaction between eye diseases and neuropathology was found. When PHF-tau quantity was evaluated in 124 decedents, the OR for the association between PHF-tau in the occipital cortex and glaucoma was 1.36 (95% CI 0.91, 2.03, p = 0.13). No statistical correction was made for multiple comparisons.
Conclusion:
Increased risk of deep cerebral microinfarcts was found in participants diagnosed with diabetic retinopathy. Eye diseases such as glaucoma may increase susceptibility to neurofibrillary tangles in the occipital cortex.
KlaverCC, OttA, HofmanA, AssinkJJ, BretelerMM, de JongPT (1999) Is age-related maculopathy associated with Alzheimer’s disease? The Rotterdam Study. Am J Epidemiol150, 963–968.
2.
TsaiD-C, ChenS-J, HuangC-C, YuanM-K, LeuH-B (2015) Age-related macular degeneration and risk of degenerative dementia among the elderly in Taiwan: A population-based cohort study. Ophthalmology122, 2327–2335.e2.
3.
KeenanTDL, GoldacreR, GoldacreMJ (2014) Associations between age-related macular degeneration, Alzheimer disease, and dementia: Record linkage study of hospital admissions. JAMA Ophthalmol132, 63–68.
van DuinkerkenE, IjzermanRG, KleinM, MollAC, SnoekFJ, ScheltensP, PouwelsPJW, BarkhofF, DiamantM, TijmsBM (2016) Disrupted subject-specific gray matter network properties and cognitive dysfunction in type 1 diabetes patients with and without proliferative retinopathy. Hum Brain Mapp37, 1194–1208.
6.
GoldwaserEL, AcharyaNK, SarkarA, GodseyG, NageleRG (2016) Breakdown of the cerebrovasculature and blood-brain barrier: A mechanistic link between diabetes mellitus and Alzheimer’s disease. J Alzheimers Dis54, 445–456.
7.
McKhannG, DrachmanD, FolsteinM, KatzmanR, PriceD, StadlanEM (1984) Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology34, 939–939.
8.
LeeCS, LarsonEB, GibbonsLE, LeeAY, McCurrySM, BowenJD, McCormickWC, CranePK (2019) Associations between recent and established ophthalmic conditions and risk of Alzheimer’s disease. Alzheimers Dement15, 34–41.
9.
HymanBT, PhelpsCH, BeachTG, BigioEH, CairnsNJ, CarrilloMC, DicksonDW, DuyckaertsC, FroschMP, MasliahE, MirraSS, NelsonPT, SchneiderJA, ThalDR, ThiesB, TrojanowskiJQ, VintersHV, MontineTJ (2012) National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimers Dement8, 1–13.
10.
MontineTJ, PhelpsCH, BeachTG, BigioEH, CairnsNJ, DicksonDW, DuyckaertsC, FroschMP, MasliahE, MirraSS, NelsonPT, SchneiderJA, ThalDR, TrojanowskiJQ, VintersHV, HymanBT, National Institute on Aging, Alzheimer’s Association (2012) National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: A practical approach. Acta Neuropathol123, 1–11.
11.
TengEL, HasegawaK, HommaA, ImaiY, LarsonE, GravesA, SugimotoK, YamaguchiT, SasakiH, ChiuD (1994) The Cognitive Abilities Screening Instrument (CASI): A practical test for cross-cultural epidemiological studies of dementia. Int Psychogeriatr6, 45–58; discussion 62.
12.
KukullWA, HigdonR, BowenJD, McCormickWC, TeriL, SchellenbergGD, van BelleG, JolleyL, LarsonEB (2002) Dementia and Alzheimer disease incidence: A prospective cohort study. Arch Neurol59, 1737–1746.
13.
LarsonEB, WangL, BowenJD, McCormickWC, TeriL, CraneP, KukullW (2006) Exercise is associated with reduced risk for incident dementia among persons 65 years of age and older. Ann Intern Med144, 73–81.
14.
SonnenJA, LarsonEB, HaneuseS, WoltjerR, LiG, CranePK, CraftS, MontineTJ (2009) Neuropathology in the adult changes in thought study: A review. J Alzheimers Dis18, 703–711.
SonnenJA, LarsonEB, CranePK, HaneuseS, LiG, SchellenbergGD, CraftS, LeverenzJB, MontineTJ (2007) Pathological correlates of dementia in a longitudinal, population-based sample of aging. Ann Neurol62, 406–413.
17.
BraakH, AlafuzoffI, ArzbergerT, KretzschmarH, Del TrediciK (2006) Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol112, 389–404.
18.
MirraSS, HeymanA, McKeelD, SumiSM, CrainBJ, BrownleeLM, VogelFS, HughesJP, van BelleG, BergL (1991) The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology41, 479–486.
19.
McKeithIG, DicksonDW, LoweJ, EmreM, O’BrienJT, FeldmanH, CummingsJ, DudaJE, LippaC, PerryEK, AarslandD, AraiH, BallardCG, BoeveB, BurnDJ, CostaD, Del SerT, DuboisB, GalaskoD, GauthierS, GoetzCG, Gomez-TortosaE, HallidayG, HansenLA, HardyJ, IwatsuboT, KalariaRN, KauferD, KennyRA, KorczynA, KosakaK, LeeVMY, LeesA, LitvanI, LondosE, LopezOL, MinoshimaS, MizunoY, MolinaJA, Mukaetova-LadinskaEB, PasquierF, PerryRH, SchulzJB, TrojanowskiJQ, YamadaM, Consortium onDLB (2005) Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium. Neurology65, 1863–1872.
20.
WhiteL, PetrovitchH, HardmanJ, NelsonJ, DavisDG, RossGW, MasakiK, LaunerL, MarkesberyWR (2002) Cerebrovascular pathology and dementia in autopsied Honolulu-Asia Aging Study participants. Ann N Y Acad Sci977, 9–23.
21.
PostupnaN, RoseSE, BirdTD, Gonzalez-CuyarLF, SonnenJA, LarsonEB, KeeneCD, MontineTJ (2012) Novel antibody capture assay for paraffin-embedded tissue detects wide-ranging amyloid beta and paired helical filament-tau accumulation in cognitively normal older adults. Brain Pathol22, 472–484.
22.
BerkeEM, KoepsellTD, MoudonAV, HoskinsRE, LarsonEB (2007) Association of the built environment with physical activity and obesity in older persons. Am J Public Health97, 486–492.
23.
DublinS, AndersonML, HeckbertSR, HubbardRA, SonnenJA, CranePK, MontineTJ, LarsonEB (2014) Neuropathologic changes associated with atrial fibrillation in a population-based autopsy cohort. J Gerontol A Biol Sci Med Sci69, 609–615.
24.
DublinS, WalkerRL, GraySL, HubbardRA, AndersonML, YuO, MontineTJ, CranePK, SonnenJA, LarsonEB (2017) Use of analgesics (opioids and nonsteroidal anti-inflammatory drugs) and dementia-related neuropathology in a community-based autopsy cohort. J Alzheimers Dis58, 435–448.
25.
CranePK, WalkerRL, SonnenJ, GibbonsLE, MelroseR, HassenstabJ, KeeneCD, PostupnaN, MontineTJ, LarsonEB (2016) Glucose levels during life and neuropathologic findings at autopsy among people never treated for diabetes. Neurobiol Aging48, 72–82.
26.
HaneuseS, SchildcroutJ, CraneP, SonnenJ, BreitnerJ, LarsonE (2009) Adjustment for selection bias in observational studies with application to the analysis of autopsy data. Neuroepidemiology32, 229–239.
27.
PattonN, AslamT, MacgillivrayT, PattieA, DearyIJ, DhillonB (2005) Retinal vascular image analysis as a potential screening tool for cerebrovascular disease: A rationale based on homology between cerebral and retinal microvasculatures. J Anat206, 319–348.
28.
HughesS, YangH, Chan-LingT (2000) Vascularization of the human fetal retina: Roles of vasculogenesis and angiogenesis. Invest Ophthalmol Vis Sci41, 1217–1228.
29.
LassenNA (1964) Autoregulation of cerebral blood flow. Circ Res15(Supp), 201–204.
30.
HarrisA, Jonescu-CuypersC, MartinB, KagemannL, ZalishM, GarzoziHJ (2001) Simultaneous management of blood flow and IOP in glaucoma. Acta Ophthalmol Scand79, 336–341.
31.
de JongFJ, SchrijversEMC, IkramMK, KoudstaalPJ, de JongPTVM, HofmanA, VingerlingJR, BretelerMMB (2011) Retinal vascular caliber and risk of dementia: The Rotterdam Study. Neurology76, 816–821.
32.
IkramMK, De JongFJ, Van DijkEJ, PrinsND, HofmanA, BretelerMMB, De JongPTVM (2006) Retinal vessel diameters and cerebral small vessel disease: The Rotterdam Scan Study. Brain129, 182–188.
33.
IkramMK, de JongFJ, VernooijMW, HofmanA, NiessenWJ, van der LugtA, KlaverCC, IkramMA (2013) Retinal vascular calibers associate differentially with cerebral gray matter and white matter atrophy. Alzheimer Dis Assoc Disord27, 351–355.
34.
IseriPK, AltinaşO, TokayT, YükselN (2006) Relationship between cognitive impairment and retinal morphological and visual functional abnormalities in Alzheimer disease. J Neuroophthalmol26, 18–24.
35.
BamboMP, Garcia-MartinE, PinillaJ, HerreroR, SatueM, OtinS, FuertesI, MarquesML, PabloLE (2014) Detection of retinal nerve fiber layer degeneration in patients with Alzheimer’s disease using optical coherence tomography: Searching new biomarkers. Acta Ophthalmol92, e581–e582.
36.
BlanksJC, SchmidtSY, TorigoeY, PorrelloKV, HintonDR, BlanksRH (1996) Retinal pathology in Alzheimer’s disease. II. Regional neuron loss and glial changes in GCL. Neurobiol Aging17, 385–395.
37.
BerishaF, FekeGT, TrempeCL, McMeelJW, SchepensCL (2007) Retinal abnormalities in early Alzheimer’s disease. Invest Ophthalmol Vis Sci48, 2285–2289.
38.
GorelickPB, ScuteriA, BlackSE, DecarliC, GreenbergSM, IadecolaC, LaunerLJ, LaurentS, LopezOL, NyenhuisD, PetersenRC, SchneiderJA, TzourioC, ArnettDK, BennettDA, ChuiHC, HigashidaRT, LindquistR, NilssonPM, RomanGC, SellkeFW, SeshadriS, American Heart Association Stroke Council, Council on Epidemiology and Prevention, Council on Cardiovascular Nursing, Council on Cardiovascular Radiology and Intervention, and Council on Cardiovascular Surgery and Anesthesia (2011) Vascular contributions to cognitive impairment and dementia: A statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke42, 2672–2713.
39.
IncePG, MinettT, ForsterG, BrayneC, WhartonSB, Medical Research Council Cognitive Function and Ageing Neuropathology Study (2017) Microinfarcts in an older population-representative brain donor cohort (MRC CFAS): Prevalence, relation to dementia and mobility, and implications for the evaluation of cerebral small vessel disease. Neuropathol Appl Neurobiol43, 409–418.
40.
BeltramoE, PortaM (2013) Pericyte loss in diabetic retinopathy: Mechanisms and consequences. Curr Med Chem20, 3218–3225.
41.
van VeluwSJ, ShihAY, SmithEE, ChenC, SchneiderJA, WardlawJM, GreenbergSM, BiesselsGJ (2017) Detection, risk factors, and functional consequences of cerebral microinfarcts. Lancet Neurol16, 730–740.
42.
LiuY, YangJ, TaoL, LvH, JiangX, ZhangM, LiX (2017) Risk factors of diabetic retinopathy and sight-threatening diabetic retinopathy: A cross-sectional study of 13 473 patients with type 2 diabetes mellitus in mainland China. BMJ Open7, e016280.
43.
TingDSW, CheungGCM, WongTY (2016) Diabetic retinopathy: Global prevalence, major risk factors, screening practices and public health challenges: A review. Clin Exp Ophthalmol44, 260–277.
44.
ArvanitakisZ, CapuanoAW, LeurgansSE, BuchmanAS, BennettDA, SchneiderJA (2016) The relationship of cerebral vessel pathology to brain microinfarcts. Brain Pathol27, 77–85.
45.
Crosby-NwaobiRR, SivaprasadS, AmielS, ForbesA (2013) The relationship between diabetic retinopathy and cognitive impairment. Diabetes Care36, 3177–3186.
46.
HarwerthRS, Carter-DawsonL, ShenF, SmithEL3rd, CrawfordML (1999) Ganglion cell losses underlying visual field defects from experimental glaucoma. Invest Ophthalmol Vis Sci40, 2242–2250.
47.
HarwerthRS, QuigleyHA (2006) Visual field defects and retinal ganglion cell losses in patients with glaucoma. Arch Ophthalmol124, 853–859.
